Moreover, pharmacological inhibition of BRISC alleviates NLRP3-driven diseases in mouse models including methionine-choline-deficient (MCD) diet-induced nonalcoholic fatty liver disease [30], which indicates a potential role of BRISC in liver diseases. This evidence concerns the gene NLRP3 and liver disorder.